GSK Respiratory Syncytial Virus Vaccine Phase 3 Trial Meets Primary Endpoint
October 13 2022 - 2:45AM
Dow Jones News
By Michael Susin
GSK PLC said Thursday that a Phase 3 trial of its respiratory
syncytial virus vaccine candidate for adults aged over 60 years met
its primary endpoint.
The U.K.-based maker of cancer and asthma medications said that
the vaccine candidate study showed a 94.1% reduction in severe RSV
disease, and overall vaccine efficacy of 82.6%, meeting the trial's
primary endpoint. The vaccine was also well tolerated with a
favorable safety profile, it added.
GSK said that regulatory submissions based on the results are
anticipated in the second half of 2022.
"These are truly exceptional results given that today RSV
remains one of the major infectious diseases without a vaccine,
despite over 60 years of research," Chief Scientific Officer Tony
Wood said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
October 13, 2022 02:30 ET (06:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jun 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024